June 2007，Sichuan Clover was established as a research laboratory.
December 2011，We completed the Angel Round Investment and raised RMB10 million.
November 2015，Sichuan Clover completed an IND filing for SCB-808.
December 2015，Sichuan Clover initiated GLP studies on SCB-313 at the National Shanghai Center for New Drug Safety Evaluation and Research.
January 2016，Sichuan Clover commenced research on its HIV subunit vaccine.
July 2016，Sichuan Clover entered into an agreement to establish and build 32,000 sqm commercial-scale cGMP biomanufacturing facility in Changxing, Zhejiang Province, China.
December 2017，We completed the Series A Investment and raised approximately RMB62.8 million.
June 2018，The first patient in a Phase 1 clinical trial was dosed with SCB-313 for treatment of malignant ascites in cancer patients.
November 2019，We completed the Series B Investment and raised approximately RMB304.1 million.
January 2020，we initiated development of SCB-2019, our COVID-19 vaccine candidate.
April 2020，We obtained funding from and established collaboration with CEPI for SCB-2019 (CpG 1018/Alum).
May 2020，We completed the Series B-2 Investment and raised approximately RMB171.8 million.
June 2020，The first participant in a Phase 1 clinical trial was dosed with SCB-2019 (CpG 1018/Alum).
November 2020，CEPI extended our partnership and increased funding up to $328 million for SCB-2019 development through licensure.
December 2020，We announced positive Phase 1 data for SCB-2019 (CpG 1018/Alum), our COVID-19 vaccine candidate.
February 2021，We completed the Series C financing raising approximately US$230 million.
March 2021，We initiated SPECTRA, a pivotal global Phase 2/3 clinical trial evaluating SCB 2019 (CpG 1018/Alum) for vaccine efficacy and dosed the first participant at a clinical trial site located in the Philippines.
June 2021，Global enrollment of SPECTRA surpassed 29,000 adult and elderly participants resulting in one of the most ethnically diverse COVID-19 clinical trials conducted to date.
June 2021，We completed an advanced purchase agreement with GAVI to supply up to 414 million doses of our COVID-19 vaccine candidate for procurement through the COVAX Facility.
June 2021，We completed a commercial supply agreement with Dynavax for their CpG 1018 adjuvant for use in our COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).